Menu

Be sure to take a good look at the pharmacy’s customer support and medicine service availability on Essenceapotek. You intend to make certain you contact MPs in many ways and that you can communicate all night to get to get assist if anything fails together with your medicine.

22 Jul

The comprehensive study of the group of Prof. Kasaj confirms that mucoderm can be used as a carrier of bioactive fluids (Emdogain® and PRF®) to improve the clinical outcome. Coating of the porcine collagen matrix mucoderm® with Emdogain® and PRF-resulted in improved cell behavior (cell attachment, proliferation, migration) of human umbilical vein endothelial cells in vitro. Therefore, the application of bioactive fluids to mucoderm® could be useful with regard to the clinical outcome and healing process in periodontal plastic surgery and implantology. Biofunctionalization of porcine-derived collagen matrix using enamel matrix derivative and platelet-rich fibrin: influence on mature endothelial cell characteristics in vitro. Park et al. 2017; Clin Oral Investig. doi: 10.1007/s00784-017-2170-7. https://www.ncbi.nlm.nih.gov/pubmed/28695450  ...

14 Jul

With the introduction of permamem®, botiss expands its regeneration system by offering an exceptionally thin, non-resorbable, biologically inert and biocompatible membrane made of 100% high-density polytetrafluoroethylene (PTFE). permamem® maintains its structural integrity during implantation and over time. Due to its small pore size the membrane acts as an efficient barrier against bacterial and cellular penetration, and may therefore be left in place for open healing in certain clinical indications. permamem® can easily be removed after the desired healing time with a pair of tweezers. After removal, the primary healing process and the reepithelialization of the regenerating soft tissue will be completed within one month. permamem® fulfills the requirements of biocompatibility according to EN ISO 10993-1 and EN ISO 7405. The biocompatibility of the membrane has been proven by in vivo preclinical data [1]. > MORE ABOUT PERMAMEM® [1] Barbeck M. et al. unpublished...

29 Jun

Launch: botiss has extended their 360° regeneration system   A new star is born: permamem® The new synthetic high-density PTFE barrier membrane for the regeneration of dental bone defects that is engineered for open healing in certain clinical indications. . permamem® is now available in many countries.   [button size="large" target="_blank" hover_type="default" text="All product informations" link="https://botiss-dental.com/products/permamem/" color="#ffffff" background_color="#00ccff" border_color="#ffffff"]...

06 Jan

Last year more than 20 scientific articles were published on botiss' hard and soft tissue products. Among the most recent ones, have a look at the: - NEW STUDY on cerabone® - NEUE STUDIE zu maxresorb® Take a look at our compilation of published scientific articles on botiss-dental.com and botiss.com.    ...

24 Dec

[vc_row row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" css_animation=""][vc_column][vc_column_text] Dear Customers, During the Christmas holidays (24.12.2016 to 01.01.2017) our office is only partly occupied. We will process your requests on January 2nd. Thank you very much for your understanding. Your botiss biomaterials Team [/vc_column_text][/vc_column][/vc_row]...

20 Dec

A new study about a sinus floor elevation method has recently been published in the International Journal of Oral & Maxillofacial Implants, where cerabone® has been used as the unique grafting material: Tawil G, Tawil P, Khairallah A. Sinus Floor Elevation Using the Lateral Approach and Bone Window Repositioning I: Clinical and Radiographic Results in 102 Consecutively Treated Patients Followed from 1 to 5 Years. Int J Oral Maxillofac Implants. 2016 Jul-Aug;31(4):827-34.) Objectives: The goal of this study was to determine the clinical outcome of the lateral sinus floor elevation technique with the repositioning of the bone window. 109 sinus lifts were performed on 102 patients. Following lateral window preparation and lifting of the sinus mucosa, the sinus was grafted with small cerabone® granules. 205 implants were placed (160 simultaneously with grafting; 45 six months after grafting) and the patients were followed up for 12 to 60 months. Conclusions: The lateral sinus elevation with window...

19 Dec

A recent study from the group of Prof. Miron of the College of Dental Medicine, at the Nova Southeastern University, FL (USA), confirmed the following properties of maxresorb®: Ideal rough surface Great potential to absorb/release growth factors, such as rhBMP2 and rhBMP9 Significant stimulation of osteoblast differentiation These are all crucial properties for bony regeneration! Published in: Clin Oral Investig. 2016 Oct 22. [Epub ahead of print]. Recombinant human bone morphogenetic protein (rhBMP)9 induces osteoblast differentiation when combined with demineralized freeze-dried bone allografts (DFDBAs) or biphasic calcium phosphate (BCP). Fujioka-Kobayashi M, Schaller B, Zhang Y, Kandalam U, Hernandez M, Miron RJ. More information on maxresorb® at https://botiss-dental.com/products/maxresorb/ The study is available here: https://www.ncbi.nlm.nih.gov/pubmed/27771827...

16 Dec

On November the 25th, the 2nd mucoderm® expert meeting has taken place in Hamburg, Germany. The aim of the meeting was to review the currently available clinical/scientific data, in order to set up further guidelines for the use of the porcine matrix in established indications and explore new fields of indications/limitations of mucoderm®. To this end, botiss and Straumann invited seven experienced clinicians with different specializations. Prof. Dr. Adrian Kasaj (University of Mainz, Germany), Dr. Raluca Cosgarea (University Cluij-Napocca, Romania and Marburg, Germany), and Dr. Attila Horváth (University of Budapest, Hungary) presented their results obtained with mucoderm® in combination with the modified coronally advanced tunnel or the Zucchelli technique for the treatment of gingival recessions, showing predictable results for Miller class I and II recessions. Dr. Dominiki Chatzopoulou (University of London, UK) pointed out the potential benefits of combining mucoderm® with Emdogain®, particularly for compromised patients and smokers. Dr. Alessandro Rossi (University...

13 Dec

A new study about a novel liquid carrier system for enamel matrix proteins in combination with collacone® has recently been published: Miron RJ, Fujioka-Kobayashi M, Zhang Y, Sculean A, Pippenger B, Shirakata Y, Kandalam U, Hernandez M. Osteogain® loaded onto an absorbable collagen sponge induces attachment and osteoblast differentiation of ST2 cells in vitro. Clin Oral Investig. 2016 Dec 1. [Epub ahead of print] https://www.ncbi.nlm.nih.gov/pubmed/27909893 Objectives: The goal of this study was to determine the potential of Osteogain®, a liquid carrier for enamel matrix derivative, in combination with collacone® as a regenerative therapy for extraction socket management. The collacone® sponge was loaded with Osteogain® and the protein resorption and release as well as osteoblast binding and differentiation were investigated. Results: The proteins in Osteogain® were efficiently absorbed by collacone® and gradually released after a 10-day time period. Osteogain® induced a 50% increase in cell adhesion to collacone® and significantly stimulated cell differentiation as evidenced by the...

16 Nov

Parallel to the DGI annual meeting, the second expert meeting on mucoderm® will take place in Hamburg on 25.11. The group of international renowned clinicians will discuss recent study results, the current state of scientific evidence as well as surgical procedures and protocols for the following indications: recession coverage, augmentation of the attached gingiva and soft tissue thickening. We are looking forward to the stimulating exchange of scientific/clinical knowledge and the resulting outcome.  ...